clenbuterol has been researched along with Cardiovascular Stroke in 4 studies
Clenbuterol: A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.
clenbuterol : A substituted aniline that is 2,6-dichloroaniline in which the hydrogen at position 4 has been replaced by a 2-(tert-butylamino)-1-hydroxyethyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A case of non-Q myocardial infarction in a previously healthy 17-year-old body builder, who used clenbuterol, a long-acting beta(2) adrenergic agonist with anabolic and lipolytic effects, is reported." | 7.73 | Myocardial infarction in a 17-year-old body builder using clenbuterol. ( Kasprzak, JD; Kierzkowska, B; Stańczyk, J, 2005) |
| "Clenbuterol is a beta 2-agonist with anabolic properties that has not been seen previously with myocardial infarction." | 5.30 | Clenbuterol and anabolic steroids: a previously unreported cause of myocardial infarction with normal coronary arteriograms. ( Dobbs, T; Goldstein, DR; Krull, B; Plumb, VJ, 1998) |
| "A case of non-Q myocardial infarction in a previously healthy 17-year-old body builder, who used clenbuterol, a long-acting beta(2) adrenergic agonist with anabolic and lipolytic effects, is reported." | 3.73 | Myocardial infarction in a 17-year-old body builder using clenbuterol. ( Kasprzak, JD; Kierzkowska, B; Stańczyk, J, 2005) |
| "Clenbuterol is a potent beta-2 agonist widely misused by professional athletes and bodybuilders." | 3.01 | Adverse events of clenbuterol among athletes: a systematic review of case reports and case series. ( Kumari, S; Pal, B; Prabhakar, PK; Sahu, SK; Tewari, D, 2023) |
| "Clenbuterol pretreatment provides significant cardioprotection against ischaemia/reperfusion injury and this is mediated by the beta(2)-adrenoceptor-G(i)-protein signalling." | 1.36 | Beta(2)-adrenoceptor agonist clenbuterol reduces infarct size and myocardial apoptosis after myocardial ischaemia/reperfusion in anaesthetized rats. ( Feng, M; Fu, Q; Hu, B; Liu, H; Wang, X; Xiang, J; Zhang, Q, 2010) |
| "Clenbuterol is a beta 2-agonist with anabolic properties that has not been seen previously with myocardial infarction." | 1.30 | Clenbuterol and anabolic steroids: a previously unreported cause of myocardial infarction with normal coronary arteriograms. ( Dobbs, T; Goldstein, DR; Krull, B; Plumb, VJ, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kumari, S | 1 |
| Pal, B | 1 |
| Sahu, SK | 1 |
| Prabhakar, PK | 1 |
| Tewari, D | 1 |
| Zhang, Q | 1 |
| Xiang, J | 1 |
| Wang, X | 1 |
| Liu, H | 1 |
| Hu, B | 1 |
| Feng, M | 1 |
| Fu, Q | 1 |
| Kierzkowska, B | 1 |
| Stańczyk, J | 1 |
| Kasprzak, JD | 1 |
| Goldstein, DR | 1 |
| Dobbs, T | 1 |
| Krull, B | 1 |
| Plumb, VJ | 1 |
1 review available for clenbuterol and Cardiovascular Stroke
| Article | Year |
|---|---|
Adverse events of clenbuterol among athletes: a systematic review of case reports and case series.
Topics: Adrenergic beta-Agonists; Cardiomyopathies; Clenbuterol; Humans; Myocardial Infarction; Myocardial I | 2023 |
3 other studies available for clenbuterol and Cardiovascular Stroke
| Article | Year |
|---|---|
Beta(2)-adrenoceptor agonist clenbuterol reduces infarct size and myocardial apoptosis after myocardial ischaemia/reperfusion in anaesthetized rats.
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Animals; Apoptosis; Clenbuterol; GTP- | 2010 |
Myocardial infarction in a 17-year-old body builder using clenbuterol.
Topics: Adolescent; Anabolic Agents; Clenbuterol; Doping in Sports; Humans; Male; Myocardial Infarction; Rad | 2005 |
Clenbuterol and anabolic steroids: a previously unreported cause of myocardial infarction with normal coronary arteriograms.
Topics: Adrenergic beta-Agonists; Adult; Anabolic Agents; Clenbuterol; Coronary Angiography; Drug Synergism; | 1998 |